nach oben

Erschienen in:

01.04.2014 | Original Article

Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network

verfasst von: Katsuhito Hori, Norihiro Kobayashi, Hitoshi Atsumi, Akira Nagayama, Masako Kondoh, Ichiro Noge, Midori Kimura, Hiroaki Utsugi, Tsuyoshi Iwasaki, Masaki Nakamura, Tomomi Kimura

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Objective

Prophylaxis of chemotherapy (CT)-induced nausea and vomiting (CINV) is important for patient’s quality of life and adherence to CT. Neurokinin receptor antagonist (NK1 antagonist) was marketed in Japan in December 2009 and the first guideline for antiemetics for CINV was released in May 2010 from Japan Society of Clinical Oncology (JSCO). We assessed changes in compliance with the JSCO guideline during the first 18 months from the launch of NK1 antagonist in Japan.

Methods

Patient-level data was extracted locally using a nationwide distributed research network consisting of 39 hospitals. Monthly compliance rates for acute (day of CT) and delayed (days 2–5) phases were summarized according to the emetic risks.

Results

In total, 81,739 CTs for 9,978 patients were analyzed. Prescription of oral NK1 antagonist was started in 31/39 hospitals during the study period. The compliance in acute phase for high emetic risk (HER) CTs gradually improved up to 39.3 % whereas it reached only to 10–15 % in delayed phase. The extra use of antiemetics decreased inversely to the increased compliance. Better compliance for HER CTs was associated with opioid use, younger age, second or later cycles, and CT regimens. Compliance in acute phase was better in inpatient whereas that in delayed phase was better in outpatients.

Conclusions

A multi-hospital survey revealed that more than half of the HER CTs remained without accompanying the standard antiemetic therapies. Association with the compliance and CINV outcomes would be also interesting to explore.

Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20(1):107–117. doi:10.1007/s00520-010-1073-9 PubMedCentralPubMedCrossRef

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112–4119. doi:10.1200/JCO.2003.01.095 PubMedCrossRef

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098. doi:10.1002/cncr.11433 PubMedCrossRef

Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit R, Carides AD, Taylor A, Evans JK, Horgan KJ (2005) The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 41(9):1278–1285PubMedCrossRef

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 29(11):1495–1501. doi:10.1200/JCO.2010.31.7859 PubMedCrossRef

Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K (2010) Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 101(11):2455–2461. doi:10.1111/j.1349-7006.2010.01689.x PubMedCrossRef

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198. doi:10.1200/JCO.2010.34.4614 PubMedCrossRef

National Comprehensive Cancer Network (2012) NCCN Clinical Practice Guidelines in Oncology: Antiemesis, V. [http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf], Accessed March 14, 2012

Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243. doi:10.1093/annonc/mdq194 PubMedCrossRef

10.

Japan Society of Clinical Oncology (2010) Guideline: appropriate use of antiemetics (in Japanese). Kanehara & Co., Ltd., Tokyo

11.

Italian Group for Antiemetic Research (1998) Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 9(7):759–765. doi:10.1023/A:1017132123411 CrossRef

12.

Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. doi:10.1093/annonc/mds021

13.

Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O (2012) Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 20(1):141–147. doi:10.1007/s00520-010-1079-3 PubMedCrossRef

14.

Kaiser R (2005) Antiemetic guidelines: are they being used? Lancet Oncol 6(8):622–625. doi:10.1016/S1470-2045(05)70284-9 PubMedCrossRef

15.

Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21(7):1373–1378. doi:10.1200/JCO.2003.08.118 PubMedCrossRef

16.

Nolte MJ, Berkery R, Pizzo B, Baltzer L, Grossano D, Lucarelli CD, Kris MG (1998) Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 16(2):771–778PubMed

17.

Abe T, Yokoyama T, Kurokawa Y, Hiroko H, Miyasato A, Osato Y, Suzuki Y, Ohyashiki K (2012) Proper use of antiemetic drugs in an outpatient chemotherapy center. J Tokyo Med Univ 70:15–25

18.

Nomura M, Abe N, Jobu K, Yagi Y, Onogawa M, Miyamura M (2011) Evaluation of antiemetic therapy based on new Japanese guidelines for antiemetic therapy. J Jpn Soc Hosp Pharm 47:1549–1552

19.

Hori K, Kobayashi N, Kimura T, Atsumi H, Nagayama A, Kondoh M, Noge I, Kimura M, Utsugi H, Iwasaki T, Nakamura M, Kimura M, Kawakami J (2012) Development of a distributed research network in Japan: a pilot study on antiemetics use for chemotherapy induced nausea and vomiting. Pharmacoepidemiol Drug Saf 21(suppl 3):458

20.

Kimura M, Tani S, Watanabe H, Naito Y, Sakusabe T, Nakaya J, Sasaki F, Numano T, Furuta T (2008) High speed clinical data retrieval system with event time sequence feature: with 10 years of clinical data of Hamamatsu University Hospital CPOE. Methods Inf Med 47(6):560–568. doi:10.3414/ME9125 PubMed

21.

Hashikata H, Harada K, Kagimura T, Nakamura M, Koizumi A (2011) Usefulness of a large automated health records database in pharmacoepidemiology. Environ Health Prev Med 16(5):313–319PubMedCentralPubMedCrossRef

22.

R Development Core Team (2010) R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. Available from [http://www.R-project.org]. Accessed 14 March 2012

23.

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115–124. doi:10.1016/S1470-2045(08)70313-9 PubMedCrossRef

24.

Wang K, Li P, Chen L, Kato K, Kobayashi M, Yamauchi K (2010) Impact of the Japanese diagnosis procedure combination-based payment system in Japan. J Med Syst 34(1):95–100PubMedCrossRef

25.

Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261–2268. doi:10.1002/cncr.20230 PubMedCrossRef

Titel: Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network
verfasst von: Katsuhito Hori
Norihiro Kobayashi
Hitoshi Atsumi
Akira Nagayama
Masako Kondoh
Ichiro Noge
Midori Kimura
Hiroaki Utsugi
Tsuyoshi Iwasaki
Masaki Nakamura
Tomomi Kimura
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 4/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-013-2048-4

Springer Medizin

Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network